VERDICT: Go SCRC! Tut Despite the fact that SCR
Post# of 7769
Posted On: 01/15/2015 9:39:24 AM
VERDICT: Go SCRC! Tut
Despite the fact that SCRC has yet to deliver any of their RapiMed® products into the Chinese market, and continues to “evolve” its business plan, the company has focused on several large, growing, and underserved markets. The company has competed against a number of larger and better known pharmaceutical distributors, successfully expanded its business lines, and strengthened its balance sheet. The company appears to be poised to continue strong growth into 2015. An “up listing” of the company’s stock and additional announcements, such as earnings for Q4 2014, have the potential to continue the recent upward movement in the price for the company’s stock.
Despite the fact that SCRC has yet to deliver any of their RapiMed® products into the Chinese market, and continues to “evolve” its business plan, the company has focused on several large, growing, and underserved markets. The company has competed against a number of larger and better known pharmaceutical distributors, successfully expanded its business lines, and strengthened its balance sheet. The company appears to be poised to continue strong growth into 2015. An “up listing” of the company’s stock and additional announcements, such as earnings for Q4 2014, have the potential to continue the recent upward movement in the price for the company’s stock.
(0)
(0)ScripsAmerica Inc (SCRC) Stock Research Links
Scroll down for more posts ▼